U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C25H35NO5
Molecular Weight 429.5491
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEBEVERINE

SMILES

CCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC2=CC=C(OC)C=C2

InChI

InChIKey=VYVKHNNGDFVQGA-UHFFFAOYSA-N
InChI=1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con744437.pdf | https://www.ncbi.nlm.nih.gov/pubmed/20128021

Mebeverine is an antispasmodic with a direct action on the smooth muscle of the gastrointestinal tract. The exact mechanism of action is not known, but multiple mechanisms, such as a decrease in ion channel permeabilities, blockade of noradrenaline reuptake, a local anesthetic effects, as well as weak anti-muscarinic and phosphodiesterase inhibitory effect might contribute to the local effects of Mebeverine. This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis. Most people will not have problems with Mebeverine, but some may get some side effects, such as: difficulty in breathing, swelling of face, neck, tongue or throat, skin rash, red itchy skin.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Alpha-1 adrenergic receptor (guinea pig)
Target ID: Muscarinic acetylcholine receptors (guinea pig)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Colofac

Approved Use

Colofac is used to treat symptoms of irritable bowel syndrome and similar problems.

Launch Date

2.58595193E11
Palliative
Colofac

Approved Use

This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis.

Launch Date

2.58595193E11
Palliative
Colofac

Approved Use

This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis

Launch Date

2.58595193E11
PubMed

PubMed

TitleDatePubMed
The antispasmodic drug mebeverine leads to positive amphetamine results by fluorescence polarization immunoassay (FPIA)--studies on the toxicological analysis of urine by FPIA and GC-MS.
2001 Jul-Aug
[Mebeverine-retard in relief of pain in gallstone patients].
2002
Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial.
2005 Aug 20
Potentiometric flow injection analysis of mebeverine hydrochloride in serum and urine.
2005 Jan 4
Generic and brand-name drugs. Are different criteria sufficiently taken into account before granting market authorisation?
2006
Investigative implications of the instability and metabolism of mebeverine.
2006 Mar
Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases.
2006 May
Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome.
2008 Apr
Serotonin receptor modulators in the treatment of irritable bowel syndrome.
2008 Feb
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis.
2008 Nov 13
Drug use in children: cohort study in three European countries.
2008 Nov 24
Development of membrane selective electrode for determination of the antipsychotic sulpiride in pharmaceuticals and urine.
2009
[The effectiveness of spasmolytic therapy in chronic acalculous cholecystitis].
2009
Psychological associations of irritable bowel syndrome besides panic disorder: an often overlooked reality.
2009
Validated LC-MS/MS method for determination of Alverine and one of its hydroxy metabolites in human plasma along with its application to a bioequivalence study.
2009 Jan 15
pH-Sensitive Mebeverine Microspheres for Colon Delivery.
2009 Jul
[A method for non-medicamentous treatment of irritated bowel syndrome].
2009 May-Jun
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome.
2010 Feb 7
Design and formulation of mebeverine HCl semisolid formulations for intraorally administration.
2010 Mar
Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial).
2010 Nov 18
Topical piroxicam in vitro release and in vivo anti-inflammatory and analgesic effects from palm oil esters-based nanocream.
2010 Nov 4
Development and validation of stability indicating HPLC and HPTLC methods for determination of sulpiride and mebeverine hydrochloride in combination.
2010 Sep
Autoimmune hepatitis triggered by nitrofurantoin: a case series.
2010 Sep 23
Presentations of perforated colonic pathology in patients with polymyalgia rheumatica: two case reports.
2010 Sep 6
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Patents

Sample Use Guides

One tablet (135 mg) three times a day. This may be gradually reduced after a few weeks when the desired effect has been obtained. The tablets are best taken 20 minutes before meals.
Route of Administration: Oral
In Vitro Use Guide
Mebeverine (10^5-10^4 M) suppressed the amplitude of the action potential and lengthened the time between stimulation and the top of the response in non-myelinated fibres of the vagus nerve.
Name Type Language
MEBEVERINE
INN   MI   WHO-DD  
INN  
Official Name English
MEBEVERINE [MI]
Common Name English
Mebeverine [WHO-DD]
Common Name English
ARLUY
Brand Name English
BENZOIC ACID, 3,4-DIMETHOXY-, 4-(ETHYL(2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)BUTYL ESTER
Common Name English
VERATRIC ACID, 4-((ETHYL(P-METHOXY-.ALPHA.-METHYLPHENETHYL))AMINO)BUTYL ESTER
Common Name English
4-(ETHYL(P-METHOXY-.ALPHA.-METHYLPHENETHYL)AMINO)BUTYL VERATRATE
Common Name English
mebeverine [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66880
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
WHO-ATC A03AA04
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
WHO-VATC QA03AA04
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID6023238
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
PRIMARY
FDA UNII
7F80CC3NNV
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
PRIMARY
DRUG CENTRAL
1642
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
PRIMARY
CAS
3625-06-7
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
PRIMARY
RXCUI
29410
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
PRIMARY RxNorm
PUBCHEM
4031
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
PRIMARY
ECHA (EC/EINECS)
222-830-4
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
PRIMARY
SMS_ID
100000081730
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
PRIMARY
ChEMBL
CHEMBL282121
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
PRIMARY
EVMPD
SUB08662MIG
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
PRIMARY
MERCK INDEX
M7108
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
PRIMARY Merck Index
MESH
C005096
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
PRIMARY
WIKIPEDIA
MEBEVERINE
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
PRIMARY
INN
1191
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
PRIMARY
DRUG BANK
DB12554
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
PRIMARY
NCI_THESAURUS
C83909
Created by admin on Wed Jul 05 23:28:22 UTC 2023 , Edited by admin on Wed Jul 05 23:28:22 UTC 2023
PRIMARY